Moreover, we found that S3633 could significantly inhibit the production of other inflammatory cytokines, including CXCL1, IL-1β, IL-17A, IL-18, and IL-6 released by NMO-IgG stimulation and significantly improve cellular inflammatory status, whereas SB203580 could only inhibit the production of CXCL1 apart from CCL2 by NMO-IgG induction (Figure 6J). This evidence concerns the gene IL1B and neuromyelitis optica.